|Study Description:||The goal of Phase I of this clinical research study is to learn the highest |
tolerable dose of PRI-724 that can be given to patients with advanced myeloid
In Phase II, researchers will study the safety of PRI-724 combined with a
standard drug, dasatinib or cytarabine. Researchers also want to learn if
PRI-724 combined with dasatinib can help to control CML, and if PRI-724
combined with cytarabine can help control AML.
PRI-724 is designed to keep cancer cells from sending and receiving signals
that they need to grow and spread.